Home / Stocks / LFST

LifeStance Health Group (LFST, Care providers & labs) Stock Valuation & Fair Value

Mixed on our tests

LifeStance Health Group (LFST, Care providers & labs) trades at a current P/E of 98.1, about 72% below its historical normal valuation, with a forward growth estimate of 74.5% and a PEG of 1.32. Priced at its historical normal P/E of 352.0 on the same blended earnings, the 2026-11-06 close of $13.77 corresponds to about $49.40 a share. This is a valuation reference, not a price target.

How to read these numbers: the PEG ratio and current P/E versus normal P/E.

DATA AS OF 2026-11-07
Current P/E
98.1
Normal P/E
352.0
PEG
1.32
Fwd growth
74.5%
Div yield
0.0%
RSI (14)
61.7
Neutral
Technical context
  • Price $13.77 at the Nov 6 close, 6.8% above the 20-day average ($12.89) and 9.1% above the 50-day ($12.62).
  • RSI (14) at 61.7.
  • 52-week range $6.18 to $14.21: the price is 3.1% below the high and 122.8% above the low.

The Street vs SeerForecast

Wall Street's mean price target for LFST is $14.45 across 10 analysts, 4.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: mixed on our tests. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from favorable on our tests (2026-07-31) to poor on forward returns (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

Current P/E and rating by weekCurrent P/E moved from 124.2 to 95.5 between 2026-07-31 and 2026-10-30, against a normal P/E of 352.0, with 2 rating changes over 14 recorded weeks.2026-07-31: P/E 124.2, Favorable on our tests, recalculated for the week of 2026-07-312026-07-31: P/E 120.7, Favorable on our tests, recorded live 2026-08-032026-08-07: P/E 120.7, Favorable on our tests, recalculated for the week of 2026-08-072026-08-07: P/E 121.8, Favorable on our tests, recorded live 2026-08-102026-08-14: P/E 121.8, Favorable on our tests, recalculated for the week of 2026-08-142026-08-14: P/E 110.0, Favorable on our tests, recorded live 2026-08-172026-08-21: P/E 110.0, Favorable on our tests, recalculated for the week of 2026-08-212026-08-21: P/E 114.0, Favorable on our tests, recorded live 2026-08-242026-08-27: P/E 114.0, Favorable on our tests, recalculated for the week of 2026-08-272026-08-28: P/E 114.0, Favorable on our tests, recalculated for the week of 2026-08-282026-08-28: P/E 114.0, Favorable on our tests, recalculated for the week of 2026-08-302026-08-28: P/E 109.9, Favorable on our tests, recorded live 2026-08-312026-09-04: P/E 109.9, Favorable on our tests, recalculated for the week of 2026-09-052026-09-04: P/E 111.0, Favorable on our tests, recorded live 2026-09-072026-09-11: P/E 111.0, Favorable on our tests, recalculated for the week of 2026-09-122026-09-11: P/E 110.5, Favorable on our tests, recorded live 2026-09-142026-09-18: P/E 110.5, Favorable on our tests, recalculated for the week of 2026-09-192026-09-18: P/E 104.7, Favorable on our tests, recorded live 2026-09-212026-09-25: P/E 104.7, Favorable on our tests, recalculated for the week of 2026-09-262026-09-25: P/E 96.4, Mixed on our tests, recorded live 2026-09-282026-10-02: P/E 96.4, Mixed on our tests, recalculated for the week of 2026-10-032026-10-02: P/E 94.3, Mixed on our tests, recorded live 2026-10-052026-10-09: P/E 94.3, Mixed on our tests, recalculated for the week of 2026-10-102026-10-09: P/E 96.9, Mixed on our tests, recorded live 2026-10-122026-10-16: P/E 96.9, Mixed on our tests, recalculated for the week of 2026-10-172026-10-16: P/E 89.7, Mixed on our tests, recorded live 2026-10-192026-10-23: P/E 96.8, Mixed on our tests, recorded live 2026-10-262026-10-30: P/E 96.8, Poor on forward returns, recalculated for the week of 2026-10-312026-10-30: P/E 95.5, Poor on forward returns, recorded live 2026-11-02100.0200.0300.0Jul 31Aug 23Sep 15Oct 7Oct 30Normal P/E 352.0
Favorable on our testsMixed on our testsPoor on forward returnsLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.

Selected weeks: the first, the latest, every week the rating moved, and the cheapest and dearest.

WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 124.2-65%Favorable on our tests (recalculated)
2026-09-28P/E 96.4-73%Mixed on our tests (across a rating rules change)
2026-10-19P/E 89.7-75%Mixed on our tests
2026-10-31P/E 96.8-72%Poor on forward returns (recalculated) (across a rating rules change)
2026-11-02P/E 95.5-73%Poor on forward returns ← now
Show all 29 readings
WeekCurrent P/EPremium to normal P/ERating
2026-07-31P/E 124.2-65%Favorable on our tests (recalculated)
2026-08-03P/E 120.7-66%Favorable on our tests
2026-08-07P/E 120.7-66%Favorable on our tests (recalculated)
2026-08-10P/E 121.8-65%Favorable on our tests
2026-08-14P/E 121.8-65%Favorable on our tests (recalculated)
2026-08-17P/E 110.0-69%Favorable on our tests
2026-08-21P/E 110.0-69%Favorable on our tests (recalculated)
2026-08-24P/E 114.0-68%Favorable on our tests
2026-08-27P/E 114.0-68%Favorable on our tests (recalculated)
2026-08-28P/E 114.0-68%Favorable on our tests (recalculated)
2026-08-30P/E 114.0-68%Favorable on our tests (recalculated)
2026-08-31P/E 109.9-69%Favorable on our tests
2026-09-05P/E 109.9-69%Favorable on our tests (recalculated)
2026-09-07P/E 111.0-68%Favorable on our tests
2026-09-12P/E 111.0-68%Favorable on our tests (recalculated)
2026-09-14P/E 110.5-69%Favorable on our tests
2026-09-19P/E 110.5-69%Favorable on our tests (recalculated)
2026-09-21P/E 104.7-70%Favorable on our tests
2026-09-26P/E 104.7-70%Favorable on our tests (recalculated)
2026-09-28P/E 96.4-73%Mixed on our tests (across a rating rules change)
2026-10-03P/E 96.4-73%Mixed on our tests (recalculated)
2026-10-05P/E 94.3-73%Mixed on our tests
2026-10-10P/E 94.3-73%Mixed on our tests (recalculated)
2026-10-12P/E 96.9-72%Mixed on our tests
2026-10-17P/E 96.9-72%Mixed on our tests (recalculated)
2026-10-19P/E 89.7-75%Mixed on our tests
2026-10-26P/E 96.8-72%Mixed on our tests
2026-10-31P/E 96.8-72%Poor on forward returns (recalculated) (across a rating rules change)
2026-11-02P/E 95.5-73%Poor on forward returns ← now

Frequently asked questions

Is LifeStance Health Group stock overvalued?

At a current P/E of 98.1 versus its historical normal P/E of 352.0, LifeStance Health Group trades about 72% below its typical valuation, with a PEG of 1.32 on 74.5% forward growth. tickerseer currently rates it mixed on our tests.

What is LifeStance Health Group's fair value and PEG?

LifeStance Health Group trades at a current P/E of 98.1 against a historical normal P/E of 352.0, a PEG of 1.32, and a forward growth estimate of 74.5%. Priced at its historical normal P/E of 352.0 on the same blended earnings, the 2026-11-06 close of $13.77 corresponds to about $49.40 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of LifeStance Health Group changed?

tickerseer's rating moved from favorable on our tests (2026-07-31) to poor on forward returns (2026-11-02). New rating rules took effect in the week of 2026-09-28, and this rating moved across that change, so part of the move may come from the new rules rather than the company.

What is the analyst price target for LifeStance Health Group?

The mean Wall Street price target for LifeStance Health Group is $14.45 across 10 analysts, 4.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Care providers & labs. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and an AI research note where we have one. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track LFST free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.